Indication
Sickle Cell Disease
The Sickle Cell Disease pipeline: 17 tracked drugs, 8 approved for this indication.
8 approved / phase 42 Phase 32 Phase 22 Phase 1/23 Phase 1
Compare the share prices of listed companies in Sickle Cell Disease →
Total attributable cost
$3.4B
$34,477/patient
Drug spend
Not yet sourced
any · US